An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors

• Published in: International journal of molecular sciences Vol. 23; no. 7; p. 3651
• Main Authors: Salvatore, Teresa, Galiero, Raffaele, Caturano, Alfredo, Rinaldi, Luca, Di Martino, Anna, Albanese, Gaetana, Di Salvo, Jessica, Epifani, Raffaella, Marfella, Raffaele, Docimo, Giovanni, Lettieri, Miriam, Sardu, Celestino, Sasso, Ferdinando Carlo
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 26.03.2022; MDPI
• Subjects: Blood Glucose; Diabetes; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Drug dosages; Gene expression; Glucagon; Glucose; Humans; Hypoglycemia; Insulin resistance; Plasma; Review; Sodium-Glucose Transporter 2 - metabolism; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Stroke Volume; diabetic kidney disease; type 2 diabetes mellitus; cardiovascular disease; cardiorenal protection; gliflozins; cardiorenal syndrome

Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic regulation in diabetes. In addition to their glucose-lowering effects, SGLT2 inhibitors prevent both renal damage and th...